Glesatinib (MGCD265) is primarily investigated for its potential in cancer therapy, particularly in targeting receptor tyrosine kinases involved in tumor growth and metastasis. It shows strong inhibitory activity against MET, AXL, and TIE2 kinases, which are implicated in various solid tumors, including non-small cell lung cancer. By blocking these signaling pathways, glesatinib helps suppress tumor cell proliferation, survival, and angiogenesis. It has been studied in clinical trials for patients with advanced cancers, especially those with MET pathway dysregulation or resistance to other targeted therapies. Its ability to cross the blood-brain barrier also makes it a candidate for treating brain metastases. Research continues to explore its efficacy either as a monotherapy or in combination with other anticancer agents.